EUVIMEDEUVIMED entdecken
Crossref

Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece

George Gourzoulidis iD, Oresteia Zisimopoulou, Andrianos Liavas, Charalampos Tzanetakos

Expert Review of Pharmacoeconomics & Outcomes Research · 15.03.2024 · 24 (3) · 375-385

DOI: 10.1080/14737167.2023.2288249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 25.11.2023. Verfasst von George Gourzoulidis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Health Through Evidence, Athens, Greece. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pyrimidines, Aminopyridines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Pfizer Hellas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To evaluate the cost-effectiveness of lorlatinib compared to 1st generation anaplastic lymphoma kinase (ALK) TKI crizotinib, and 2nd generation TKIs alectinib and brigatinib, for previously untreated patients with ALK+ advanced Non-Small Cell Lung Cancer (aNSCLC). METHODS: A partitioned survival model was locally adapted from a Greek payer perspective over a lifetime horizon. Clinical, safety and utility data were extracted from literature. Direct medical costs reflecting the year 2023 were included in the analysis (€). Model outcomes were patients' life years (LYs), quality-adjusted life years (QALYs), total costs and incremental cost-effectiveness ratios (ICERs). RESULTS: Total cost per patient with lorlatinib, alectinib, crizotinib, and brigatinib was estimated to be €188,205, €183,343, €75,028, and €145,454 respectively. Lorlatinib appeared to yield more LYs and QALYs gained versus alectinib, crizotinib, and brigatinib. Hence, lorlatinib resulted in ICERs of €4,315 per LY gained and €4,422 per QALY gained compared to alectinib, €34,032 per LY gained and €48,256 per QALY gained versus crizotinib and €16,587 per LY gained and €26,271 per QALY gained compared to brigatinib. CONCLUSION: Lorlatinib provides substantial clinical benefit and appears to be a cost - effective treatment option compared to 1st and 2nd generation TKIs for previously untreated patients with ALK+ aNCSLC in Greece.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsPyrimidinesAminopyridinesLactamsPyrazolesOrganophosphorus CompoundsAdultHumansCrizotinibGreeceAnaplastic Lymphoma KinaseCost-Effectiveness AnalysisCost-Benefit AnalysisLactams, MacrocyclicProtein Kinase Inhibitors

Stichwörter der Autor:innen

Cost-effectivenessGreeceanaplastic lymphoma kinasefirst-line treatmentnon-small cell lung cancer

Substanzen

CrizotiniblorlatinibbrigatinibAnaplastic Lymphoma KinaseLactams, MacrocyclicProtein Kinase InhibitorsPyrimidinesAminopyridinesLactamsPyrazoles

Autor:innen und Institutionen

  • Health Through Evidence, Athens, Greece.
  • Pfizer Hellas, Athens, Greece.

ORCID-Profile: George Gourzoulidis

Förderung

  • Pfizer Hellas

Zitieren

APA

Gourzoulidis, G., Zisimopoulou, O., Liavas, A., & Tzanetakos, C. (2024). Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece. Expert Review of Pharmacoeconomics & Outcomes Research, 24(3), 375-385. https://doi.org/10.1080/14737167.2023.2288249

Vancouver

Gourzoulidis G, Zisimopoulou O, Liavas A, Tzanetakos C. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece. Expert Review of Pharmacoeconomics & Outcomes Research. 2024;24(3):375-385. doi:10.1080/14737167.2023.2288249

BibTeX
@article{Gourzoulidis2024,
  author = {Gourzoulidis, George and Zisimopoulou, Oresteia and Liavas, Andrianos and Tzanetakos, Charalampos},
  title = {Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2024},
  volume = {24},
  number = {3},
  pages = {375--385},
  doi = {10.1080/14737167.2023.2288249}
}
Kostenlos starten →